- ￥376 - 3990
- Solarbio
- 北京
- IL1800
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
LY-3009120
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1454682-72-4
- 规格：
50mg/25mg/1mg/10mg/5mg
| 规格： | 50mg | 产品价格： | ￥3990.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥2690.0 |
| 规格： | 1mg | 产品价格： | ￥376.0 |
| 规格： | 10mg | 产品价格： | ￥1340.0 |
| 规格： | 5mg | 产品价格： | ￥840.0 |
| 基本信息 | |
| CAS | No.1454682-72-4 |
| 英文名称 | LY-3009120 |
| 别名 | ;LY3009120;LY-3009120; |
| 分子式 | C23H29FN6O |
| 分子量 | 424.51 |
| 溶解性 | Soluble in DMSO ≥1mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to brown Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD28411374 |
| SMILES | O=C(NC1=CC(C2=CC3=CN=C(NC)N=C3N=C2C)=C(C)C=C1F)NCCC(C)(C)C |
| 靶点 | Raf |
| 通路 | MAPK |
| 背景说明 | LY-3009120是一种新型有效的pan-Raf抑制剂。 |
| 生物活性 | LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E， BRAFWT and CRAFWT with IC50s of 5.8， 9.1 and 15 nM， respectively.[1-4] |
| In Vitro | In the whole-cell based KiNativ assay， LY3009120 shows affinity to each RAF isoform with the IC50 of 44， 31-47 and 42 nM for ARAF， BRAF and CRAF respectively. LY3009120 exhibits anti-proliferative effects on cell lines harboring BRAFV600E， KRASG13 and KRASG12 mutations. LY3009120 (1 μM) inhibits the phosphorylation of both MEK1/2 and ERK1/2 in cell lines with high basal levels of pMEK1/2 and pERK1/2 (RKO and HCT 116)[1]. LY3009120 shows inhibitory effect on tumor cells such as BxPC-3， NCI-H2405 and OV-90 cell lines. LY3009120 (0.01 μM) demonstrates potent and dose-dependent inhibition of phospho-MEK and ERK in all three cell lines. LY3009120 demonstrates a concentration-dependent cell growth inhibition with IC50 values of 0.04， 0.087， and 0.007 μM against H2405， BxPC-3， and OV-90 cells， respectively[2]. LY3009120 inhibits BRAFWT， CRAFWT， BRAFV600E， and BRAFV600E+G468A with the IC50 values of 9.1， 15， 5.8， and 17 nM， respectively. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK. LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers[3]. LY3009120 gives only very minor activation at very low doses， with near complete inhibition of phospho-ERK at concentrations above 100 nM[4]. |
| 细胞实验 | LY3009120 (20 mg/kg bid) displays significant activity in in vivo BRAFmut and KRASmut CRC xenograft models. In Colo 205 xenografts (BRAFmut)， LY3009120 results in statistically significant tumor regression， while treatment of HCT 116 xenografts (KRASmut) results in statistically significant inhibition of tumor growth. LY3009120 treatment reduces pMEK1/2 in all HT-29 xenografts and reduces pERK1/2 in the majority of HT-29 xenografts[1]. LY3009120 (15 or 30 mg/kg) achieves almost complete tumor growth regression， and inhibits downstream phospho-MEK and ERK by approximately 70% and 60%， respectively， in the H2405 model[2]. |
| 细胞实验 | Briefly， cells are grown in McCoy’s 5A supplemented with 10% characterized fetal bovine serum at 37°C， 5% CO2， and 95% humidity. Cells are allowed to expand until 75-90% confluency at which point they are subcultured or harvested for assay use. A serial dilution of test compound is dispensed into a 384-well black clear bottom plate in triplicate. Six-hundred-twenty-five cells are added per well in 50 μL of complete growth medium in the 384-well plate. Plates are incubated for 67 h at 37°C， 5% CO2， and 95% humidity. At the end of the incubation period， 10 μL of a 440 μM solution of resazurin in PBS is added to each well of the plate and plates are incubated for an additional 5 h at 37°C， 5% CO2， and 95% humidity. Plates are read on a Synergy2 reader using an excitation of 540 nm and an emission of 600 nm. Data are analyzed using Prism softwareto calculate IC50 values.[1-4] |
| 动物实验 | Briefly， 5×106 to 10×106 tumor cells in a 1:1 Matrigel mix (0.2 mL total volume) are injected subcutaneously into the right hind flank of female NIH nude rats. After tumors reach a desired size of approximately 300 mm3， animals are randomized into groups of 8 for efficacy studies. Drugs (LY3009120 or PLX4032) are administered orally (gavage) in 0.6-mL volume of vehicle with the dose schedules. Tumor growth and body weight are monitored over time to evaluate efficacy and signs of toxicity.[1-4] |
| 数据来源文献 | [1]. Vakana E， et al. LY3009120， a panRAF inhibitor， has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget. 2017 Feb 7;8(6):9251-9266 [2]. Chen SH， et al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov. 2016 Mar;6(3):300-15 [3]. Peng SB， et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell. 2015 Sep 14;28(3):384-98 [4]. Henry JR， et al. Discovery of 1-(3，3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2，3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumo |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IL1800 LY-3009120 抑制剂/拮抗剂/激动剂 索莱宝
￥376 - 3990
